




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 19/04, 19/056, 19/06, 19/10, 19/12, 19/16, 19/20, 5/02, 5/10, 13/02, 15/04 // A61K 31/70	A1	(11) International Publication Number: WO 97/16456 (43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/KR96/00189 (22) International Filing Date: 1 November 1996 (01.11.96) (30) Priority Data: 1995/39340 2 November 1995 (02.11.95) KR (71) Applicant (for all designated States except US): CHONG KUN DANG CORP. [KR/KR]; 410, Shindorim-dong, Guro-gu, Seoul 152-070 (KR). (72) Inventors; and (75) Inventors/Applicants (for US only): KIM, Jung, Woo [KR/KR]; 925-7, Hwagong 1-dong, Kangseo-gu, Seoul 157-011 (KR). CHUNG, Koo, Hun [KR/KR]; Taegyeong Samik Apartment, A-402, Simgokbon-dong, Sosa-gu, Bucheon, Kyeonggi-do 422-240 (KR). AHN, Soon, Kil [KR/KR]; Hanra Apartment, 5-315, Gharak-dong, Songpa-gu, Seoul 138-160 (KR). SON, Hoe, Joo [KR/KR]; Cheoncheon Apartment, 105-104, Cheoncheon-dong, Changan-gu, Suwon, Kyeonggi-do 440-330 (KR). JEONG, Byeong, Seon [KR/KR]; 1524-11, Bongcheon 8-dong, Kwanak-gu, Seoul 151-058 (KR).		(74) Agent: SUH, Jong, Wan; New-Seoul Building, 3rd floor, 828-8, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: NOVEL NUCLEOSIDE DERIVATIVES AND PROCESS FOR PREPARING THE SAME**(57) Abstract**

According to the present invention, provided are novel nucleoside derivatives having anti-viral activity, in particular, anti-HBV (anti-Hepatitis-B Virus) activity, represented by general formula (I), wherein R_1 represents hydrogen, phosphate, phosphonate, alkyl or acyl, R_2 represents alkoxy or halogen, R_3 represents substituted or non-substituted pyrimidine or purine base, and X represents O, S, SO or SO₂; pharmaceutically acceptable salts thereof, and processes for preparation thereof. As the compound (I) has two or more asymmetric carbon atoms, all possible stereoisomers and mixtures thereof are included in the scope of the present invention.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE OF THE INVENTION

Novel nucleoside derivatives and process for preparing the same



5 Technical Field

The present invention relates to novel nucleoside derivatives having anti-viral activity, in particular, anti-HBV (anti-Hepatitis-B Virus) activity, represented by the following general formula(I):



10 wherein R₁ represents hydrogen, phosphate, phosphonate, alkyl or acyl, R₂ represents alkoxy or halogen, R₃ represents substituted or non-substituted pyrimidine or purine base, and X represents O, S, SO or SO₂; pharmaceutically acceptable salts thereof, and processes for preparation thereof.

15 As a compound represented by general formula (I) has two or more asymmetric carbon atoms, the compound of the present invention represented by general formula (I) exists as a cis isomer as general formula (II) or trans isomer as general formula (III), or a mixture thereof.



20

In the formula, R₁, R₂, R₃ and X are defined as above.

Each cis or trans isomer may exist as an optically pure isomer or as a

mixture, i. e. racemic mixture. All isomers and mixture thereof mentioned above are included in the compounds of the present invention.

Background Art

5 HBV is a lethal virus which causes acute or chronic viral hepatitis in human body and finally makes progress to liver cancer. Though the vaccines against the virus have been developed, a therapeutic agent has been hardly developed yet. Up to the present, Ara-A or interferon has been partially used for the treatment of hepatitis B, but both agents have
10 many problems in their activity and safety.

Recently, a variety of nucleoside compounds having anti HBV activity have been reported.

For example, it is reported that 2',3'-dideoxy-3'-thiacytidine [Proc. Natl. Acad. Sci. USA, 88, 8495 (1991)], 5-fluoro-2',3'-dideoxy-3'-thiacytidine
15 [Proc. Natl. Acad. Sci. USA, 88, 8495 (1991)], 2',3'-dideoxy- β -L-5-fluorocytidine [Biochem. Pharm., 47, 171 (1994)], and 2',3'-dideoxy- β -L-cytidine [Biochem. Pharm., 47, 171 (1994)] have anti-HBV activity.

However, these compounds leave much to be improved in view of their activity and safety, whereby development of novel compounds having
20 more activity and less toxicity has still been required.


Disclosure of the Invention

The object of the present invention is to provide novel compounds having excellent anti-HBV activity with low toxicity, which are represented
25 by general formula (I), and processes for preparation thereof.

In the compounds of the present invention, which are represented by general formula (I), R₁ represents hydrogen, phosphate, phosphonate, alkyl or acyl, R₂ represents alkoxy or halogen, R₃ represents pyrimidine or purine base which have natural origin, or their derivatives in which some portions
30 of the base have been modified, and X represents O, S, SO or SO₂, as defined above.


Among the compounds represented by general formula (I), more preferable are the compounds in which R_1 represents hydrogen, phosphate or phosphonate, R_2 represents alkoxy or halogen, R_3 represents groups represented by the following formulas, and X represents O or S.

5



In the above formulas, R_4 represents hydrogen, saturated or unsaturated alkyl which may have (a) substituent(s), or halogen, R_5 represents hydrogen, hydroxy, alkoxy, saturated or unsaturated alkyl which may have (a) substituent(s), or saturated or unsaturated acyl which may have (a) substituent(s), R_6 represents hydrogen, cyano, carboxyl, alkoxycarbonyl, carbamoyl or thiocarbamoyl, and R_7 and R_8 each represents hydrogen, hydroxy, amino or halogen.

Among the compounds represented by general formula (I), the most preferable are the compounds in which R_1 represents hydrogen, phosphate or phosphonate, R_2 represents alkoxy or halogen, R_3 represents groups represented by the following formulas, and X represents O or S.




In the above formulas, R_9 represents hydrogen, methyl, hydroxymethyl, methoxymethyl, methylthiomethyl, trifluoromethyl, ethyl, propyl, cyclopropyl, vinyl, 2-bromovinyl, fluoro, chloro, bromo or iodo, R_{10} represents hydrogen, methyl, ethyl, hydroxy, methoxy or C_1 - C_{16} acyl, R_{11} represents hydrogen, cyano, carboxyl, alkoxycarbonyl, carbamoyl or thiocarbamoyl, and R_{12} and R_{13} each represents hydrogen, hydroxy, amino, fluoro, chloro, bromo or iodo.

The compound (I) of the present invention can be prepared by a conventional method which is well-known in the field of nucleic acid chemistry, as described below.

(Method A)

According to the most common method, the compound (I) can be obtained by reacting a five-membered ring represented by general formula (IV) with an appropriate base.




In the above formula, R_{14} represents hydrogen or protective group for hydroxy group, preferably alkyl, acyl or substituted silyl group, more preferably benzyl, acetyl, benzoyl, trimethylsilyl, tert-butyldimethylsilyl or tert-butyldiphenylsilyl group, R_{15} represents alkoxy or halogen, X represents O, S, SO or SO_2 , and L represents acyl, halide or alkoxy group, more preferably acetyl group.

More specifically, the compound (I) of the present invention can be obtained by a condensation reaction of compound (IV) with a base protected with a silyl group in the presence of a Lewis acid catalyst. As a desirable solvent for the reaction, mentioned are dichloromethane, 1,2-dichloroethane and acetonitrile. As a desirable Lewis acid catalyst, mentioned are tin chloride, titanium tetrachloride and silyl compounds such as trimethylsilyl triflate.

The compound of general formula (IV), which is used as a starting material for the preparation of compound (I) of the present invention, also is a novel compound. Among the compounds represented by general formula (IV), a compound wherein X is O can be prepared as shown in the following scheme I.


Scheme I



According to the scheme I, 1,3-dihydroxyacetone is reacted with a proper hydroxy protecting group to obtain compound (VI); the compound (VI) is reacted with alkyl bromoacetate and zinc (Reformatsky Reaction) or
 5 reacted with an enolate generated by treating alkyl acetate with a strong base such as LDA to obtain compound (VII); the compound (VII) is deprotected to obtain a lactone; the primary alcohol group is protected again with a proper protective group and then the tertiary alcohol group is properly halogenated to obtain the halide compound or alkylated to obtain
 10 the alkoxy compound (VIII); the compound (VIII) is reduced by a reducing agent such as diisobutyl aluminum hydride to obtain lactole (IX), and then the lactol is acylated, alkylated or halogenated to obtain the objective compound (IV). (In the above scheme I, R₁₄ of compound VI, VII, and VIII represents hydroxy protecting group.)

15 While another compound (IV) wherein X is S can be prepared as shown in the following scheme II.

Scheme II



20 According to the scheme II, lactole (IX) is reacted with a

benzylmercaptan to obtain intermediate (X); the intermediate (X) is reacted with triphenylphosphine and iodine to obtain tetrahydrothiophene derivatives (XI); the derivatives (XI) is reacted with LH in the presence of Lewis acid to obtain the objective compound (IV).

5 And also, the compound (IV) wherein X is SO, SO₂ can be prepared by oxidizing the compound (IV) wherein X is S with a proper oxidant.

(Method B)

10 A compound (I) may be converted to another compound (I) by substituting the base with other base.

The substitution process may be a chemical method (for instance, an uracil derivative is substituted with cytosine derivative), or a method using enzyme such as deoxyribose transferase. These base substitution processes are well known in the field of nucleic acid chemistry.

15 The compounds of general formula (I) prepared by the above processes are generally obtained as a mixture of cis and trans isomers.

The mixture can be separated by a physical method such as recrystallization or chromatography.

20 The compound of general formula (I) which is optically pure can be obtained by optical resolution of the racemic mixture or asymmetric synthesis starting from optically pure compound.

25 Pharmaceutically acceptable salts of the compound can be prepared by dissolving the compound in an appropriate solvent and reacting the compound with an acid or a base. Hydrochloric acid salt of the compound is most preferable.

30 This invention provides anti-HBV agent containing nucleoside derivatives represented by general formula (I). Hereby anti-HBV agent maybe administered for an adult in a daily dose of approximately 10 mg to 500 mg as nucleoside derivatives. Anti-HBV agent of the present invention may be administered in oral or non-oral dosage form.

Best Mode for Carrying out the Invention

Here-in-after, the present invention will be described in detail by referring to the following Examples. However, it should be noted that the present invention is not restricted to these Examples.

Example 1 : 4-(t-Butyldiphenylsilyloxymethyl)-4-hydroxytetrahydrofuran-2-one(1)

To a solution of 4-hydroxy-4-hydroxymethyltetrahydrofuran-2-one (7.8 g) in dry dichloromethane (200 ml), triethylamine (9.8 ml), t-butylchlorodiphenylsilane (16.9 ml) and 4-dimethylaminopyridine (360 mg) were added, and the resultant mixture was stirred at room temperature under nitrogen atmosphere for 10 hours. The reaction mixture was evaporated under reduced pressure, and the residue purified on a silica column (25% ethyl acetate/n-hexane) to give the title compound (20 g) as a white solid.

$^1\text{H NMR}(\text{CDCl}_3) \delta : 7.31-7.50(\text{m}, 10\text{H}), 4.12(\text{s}, 2\text{H}), 3.59(\text{s}, 2\text{H}), 2.48(\text{s}, 2\text{H}), 0.99(\text{s}, 9\text{H}),$

Example 2 : 4-(t-Butyldiphenylsilyloxymethyl)-4-fluorotetrahydrofuran-2-one(2)

A solution of diethylaminosulfur trifluoride (5 ml) in dry dichloromethane (100 ml) was cooled to -78°C , and a solution of 4-(t-butyldiphenylsilyloxymethyl)-4-hydroxytetrahydrofuran-2-one (14 g) in dry dichloromethane (100 ml) was added thereto. The reaction mixture was stirred at room temperature under nitrogen atmosphere for 1 hour. A cold aqueous solution (100 ml) of 10% sodium bicarbonate was added to the reaction mixture and the resultant mixture stirred for 30 minutes. The separated organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure.

The residue was purified on a silica column (10% ethyl acetate/n-hexane) to obtain the objective compound (2.5 g) as a pale yellow liquid.

¹H NMR (CDCl₃) δ : 7.25-7.65(m, 10H), 4.51(s, 1H), 4.38(d, 1H),
3.86(s, 1H), 3.79(d, 1H), 2.86(dd, 1H), 2.73(dd, 1H), 1.07(s, 9H)

5 **Example 3 : 4-(t-Butyldiphenylsilyloxymethyl)-4-fluorotetrahydro
furan-2-ol(3)**

 A solution of 4-(t-butyldiphenylsilyloxymethyl)-4-fluorotetrahydro
furan-2-one (2.59 g) in dry dichloromethane (50 ml) was cooled to -78°C,
and 1.0 M solution (7ml) of diisobutyl aluminum hydride was added
10 thereto.

 After stirring the reaction mixture at -78°C under nitrogen atmosphere
for 30 minutes, a saturated aqueous solution (20 ml) of potassium sodium
tartrate was added thereto, and the mixture stirred at room temperature for 3
hours. The separated organic layer was dried over anhydrous magnesium
15 sulfate, filtered and concentrated under reduced pressure. Thus obtained
yellow liquid was used in the following step without further purification.

**Example 4 : 4-(t-Butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetra
hydrofuran(4)**

20 4-(t-Butyldiphenylsilyloxymethyl)-4-fluorotetrahydrofuran-2-ol
obtained in Example 3 was dissolved in dry dichloromethane (50 ml), and
triethylamine (1.1 ml), acetic anhydride (0.7 ml) and 4-dimethylamino
pyridine (42 mg) were added thereto.

 After stirring the reaction mixture at room temperature for 30 minutes,
25 water (10 ml) was added and the mixture stirred for 10 minutes. The
separated organic layer was dried over anhydrous magnesium sulfate,
filtered and concentrated under reduced pressure.

 The residue was purified on a silica column (10% ethyl acetate/n-
hexane) to obtain the objective compound (2 g) as white solid.

30

¹H NMR (CDCl₃) δ : 7.39-7.67(m, 10H), 6.45(dd, 1H), 4.08-4.29(m, 2H),

3.78-3.94(m, 2H), 2.27-2.61(m, 2H), 2.02(s, 3H), 1.07(s, 9H)

Example 5 : cis-2-(Thymin-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(5) and trans-2-(Thymin-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(6)

Thymine (303 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (20 ml), and ammonium sulfate (catalytic amount) was added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 4 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (20 ml) was added and then a solution of 4-(t-butylidiphenylsilyloxymethyl)-2-acetoxy- 4-fluorotetrahydrofuran (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.47 ml) was added dropwise, and the mixture stirred at 0°C under nitrogen atmosphere for 30 minutes. Saturated aqueous solution (20 ml) of sodium bicarbonate was added thereto, and the resultant mixture was stirred at room temperature for 30 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (50% ethyl acetate/n-hexane) to obtain the title compounds, cis-isomer (135 mg) and trans-isomer (75 mg), respectively as white solid.

Each of the obtained isomers was dissolved in THF (15 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (5% methanol/dichloromethane) to obtain the objective compounds, cis-isomer (64mg) and trans-isomer (35mg), as white solid.

trans-isomer

¹H NMR (DMSO-d₆) δ : 11.29(br. s, 1H), 7.38(s, 1H), 6.07(dd, 1H),
5.27(t, 1H), 4.30-4.22(m, 1H), 3.95-3.83(m, 1H), 3.68-3.59(m,
2H), 2.64-2.48(m, 1H), 2.22-2.17(m, 1H), 1.77(s, 3H)

5 UV (H₂O) λ_{\max} : 267.4 nm(pH 7), 267.2 nm(pH 2), 265.4 nm(pH 11)

cis-isomer

¹H NMR (DMSO-d₆) δ : 11.30(s, 1H), 7.55(d, 1H), 6.13(t, 1H),
5.25(t, 1H), 4.26-4.15(m, 1H), 3.97-3.89(m, 1H),
10 6.3.73-3.65(m, 2H), 2.43-2.26(m, 2H), 1.77(s, 3H)

UV (H₂O) λ_{\max} : 265.8 nm(pH 7), 266.0 nm(pH 2), 265.8 nm(pH 11)

**Example 6 : cis-2-(Cytosin-1-yl)-4-fluoro-4-hydroxymethyltetrahydro
furan(7) and trans-2-(cytosin-1-yl)-4-fluoro-4-hydroxymethyltetra
15 hydrofuran(8)**

N⁴-Acetylcytosine (368 mg) was suspended in 1,1,1,3,3,3-hexamethyl
disilazane (20 ml), and ammonium sulfate (catalytic amount) was added
thereto. The mixture was heated under reflux with stirring under nitrogen
atmosphere for 4 hours. Then, the mixture was evaporated under reduced
20 pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry
1,2-dichloroethane (15 ml) was added to dissolve the residue. Then, a
solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydro
furan (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to -10°C, trimethylsilyl
25 trifluoromethanesulfonate (0.47 ml) was added dropwise, and the mixture
stirred at -10°C under nitrogen atmosphere for 20 minutes. Saturated
aqueous solution (20 ml) of sodium bicarbonate was added thereto, and the
resultant mixture stirred at room temperature for 10 minutes. Insoluble
materials were removed by filtration, and the organic layer separated from
30 the filtrate was dried over anhydrous magnesium sulfate, filtered and
concentrated under reduced pressure. The residue was purified on a silica

column (ethyl acetate/n-hexane) to obtain the title compounds, cis-isomer (158 mg) and trans-isomer (157 mg), respectively as white solid. To the obtained white solid, saturated methanolic ammonia solution (7 ml) was added. The mixture stirred under nitrogen atmosphere for 30 minutes and concentrated under reduced pressure.

Each of the obtained isomers was dissolved in THF (15 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (10% methanol/dichloromethane) to obtain the objective compounds, cis-isomer (51mg) and trans-isomer (64mg), as white solid.

trans-isomer

¹H NMR (DMSO-d₆) δ : 7.53(d, 1H), 7.12-7.03(br.d, 2H), 6.02(dd, 1H),
5.71(d, 1H), 5.24(t, 1H), 4.26-4.21(m, 1H), 4.00-3.88(m, 1H),
3.66-3.57(m, 2H), 2.59-2.52(m, 1H), 2.12-2.07(m, 1H)
UV (H₂O) λ_{max} : 269.8, 229.2 (sh) nm (pH 7), 278.6,
219.6 (sh) nm (pH 2), 270.2nm(pH 11)

cis-isomer

¹H NMR (DMSO-d₆) δ : 7.60(d, 1H), 7.16-7.12(br.d, 2H), 6.10(t, 1H),
5.70(d, 1H), 5.23(t, 1H), 4.24-4.13(m, 1H), 3.98-3.89(m, 1H),
3.70-3.62(m, 2H), 2.45-2.38(m, 1H), 2.26-2.15(m, 1H)
UV (H₂O) λ_{max} : 269.4, 229.0 (sh) nm(pH 7), 278.0,
209.0 (sh) nm (pH 2), 269.8 nm (pH 11)

Example 7 : cis-2-(5-Fluorocytosin-1-yl)-4-fluoro-4-hydroxymethyl tetrahydrofuran(9) and trans-2-(5-fluorocytosin-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(10)

N⁴-Acetyl-5-fluorocytosine (621 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (16 ml), and ammonium sulfate (catalytic amount)

was added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 4 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (15 ml) was added to dissolve the residue. Then, a solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydro furan (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.47 ml) was added dropwise, and the mixture was stirred at 0°C under nitrogen atmosphere for 20 minutes. Saturated aqueous solution (20 ml) of sodium bicarbonate was added thereto, and the resultant mixture stirred at room temperature for 30 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (20% ethyl acetate/n-hexane) to obtain the title compounds, cis-isomer (321 mg) and trans-isomer (220 mg), respectively as white solid. To the obtained white solid, saturated methanolic ammonia solution (7 ml) was added. The mixture stirred under nitrogen atmosphere for 6 hours and concentrated under reduced pressure.

Each of the obtained isomers was dissolved in THF (15 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (7% methanol/chloroform) to obtain the objective compounds, cis-isomer (95mg) and trans-isomer (115mg), as white solid.

trans-isomer

¹H NMR (DMSO-d₆) δ : 7.68(br.d, 1H), 7.50(br.s, 1H), 5.97(d, 1H), 5.25(t, 1H), 4.35-4.30(m, 1H), 4.00-3.88(m, 1H), 3.66-3.57(m, 2H), 2.65-2.60(m, 1H), 2.19-2.14(m, 1H)

UV (H₂O) λ_{\max} : 279.4, 232.6 (sh) nm(pH 7), 288.6, 212.4 (sh) nm(pH 2),
278.4 nm(pH 11)

cis-isomer

5 ¹H NMR (DMSO-d₆) δ : 7.92(d, 1H), 7.85-7.12(br.s, 1H), 7.65(br.s, 1H),
6.08(t, 1H), 5.22(t, 1H), 4.28-4.16(m, 1H), 3.95-3.85(m, 1H),
3.70-3.64(m, 2H), 2.47-2.43(m, 1H), 2.27-2.15(m, 1H)

UV (H₂O) λ_{\max} : 279.6, 236.2 (sh) nm (pH 7), 286.2,
211.6 (sh) nm (pH 2), 279.2 nm (pH 11)

10

Example 8 : cis-2-(5-Fluorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(11) and trans-2-(5-fluorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(12)

15 5-Fluorouracil (310 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (15 ml), and ammonium sulfate (catalytic amount) was added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 8 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (20 ml) was added. Then, a solution
20 of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydrofuran (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.47 ml) was added dropwise, and the mixture stirred at 0°C under nitrogen atmosphere for 20 minutes. Saturated aqueous
25 solution (20 ml) of sodium bicarbonate was added thereto, and the resultant mixture stirred at room temperature for 30 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (33%
30 ethyl acetate/n-hexane) to obtain the title compounds, cis-isomer (182 mg) and trans-isomer (268 mg), respectively as white solid.

Each of the obtained isomers was dissolved in THF (7 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (66% ethyl acetate/n-hexane) to obtain the objective compounds, cis-isomer (74mg) and trans-isomer (127mg), as white solid.

trans-isomer

¹H NMR (DMSO-d₆) δ : 11.83(br.s, 1H), 7.75(d, 1H), 6.04(d.d, 1H),
5.28(t, 1H), 4.38-4.30(m, 1H), 3.98-3.89(m, 1H), 3.67-3.59(m,
2H), 2.63-2.52(m, 1H), 2.30-2.15(m, 1H)

UV (H₂O) λ_{max} : 268.6 nm(pH 7), 268.6 nm(pH2), 268.4 nm(pH 11)

cis-isomer

¹H NMR (DMSO-d₆) δ : 11.8(br.s, 1H), 8.07(d, 1H), 6.11(t, 1H),
5.25(t, 1H), 4.28-4.16(m, 1H), 3.98-3.90(m, 1H),
3.73-3.65(m, 2H), 2.48-2.28(m, 2H)

UV (H₂O) λ_{max} : 268.2 nm(pH 7), 268.2 nm(pH2), 268.0 nm(pH 11)

Example 9 : cis-2-(5-Chlorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(13) and trans-2-(5-chlorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(14)

5-Chlorouracil (312 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (15 ml), and ammonium sulfate (catalytic amount) was added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 3.5 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (20 ml) was added. Then, a solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydrofuran (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.47 ml) was added dropwise, and the mixture stirred at 0°C under nitrogen atmosphere for 20 minutes. Saturated aqueous solution (20 ml) of sodium bicarbonate was added thereto, and the resultant mixture stirred at room temperature for 30 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (50% ethyl acetate/n-hexane) to obtain the title compounds, cis-isomer (73 mg) and trans-isomer (340 mg), respectively as white solid.

Each of the obtained isomers was dissolved in THF (7 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (66% ethyl acetate/n-hexane) to obtain the objective compounds, cis-isomer (30mg) and trans-isomer (110mg), as white solid.

trans-isomer

¹H NMR (DMSO-d₆) δ : 11.86(br.s, 1H), 7.78(s, 1H), 6.05(dd, 1H),
5.28(t, 1H), 4.40-4.32(m, 1H), 3.99-3.87(m, 1H),
3.68-3.59(m, 2H), 2.64-2.53(m, 1H), 2.33-2.27(m, 1H)

UV (H₂O) λ max : 276.2 nm(pH 7), 276.4 nm(pH 2), 274.2 nm(pH 11)

cis-isomer

¹H NMR (DMSO-d₆) δ : 11.85(br.s, 1H), 8.12(s, 1H), 6.09(t, 1H),
5.25(t, 1H), 4.30-4.18(m, 1H), 4.02-3.93(m, 1H),
3.73-3.65(m, 2H), 2.45-2.41(m, 2H)

UV (H₂O) λ max : 275.6 nm(pH 7), 275.8 nm(pH 2), 273.8 nm(pH 11)

Example 10 : cis-2-(5-Iodouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(15) and trans-2-(5-iodouracil-1-yl)-4-fluoro-4-hydroxy

methyltetrahydrofuran(16)

5-Iodouracil (571 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (20 ml), and ammonium sulfate (catalytic amount) was added thereto. The mixture was heated under reflux with stirring
5 under nitrogen atmosphere for 2 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (20 ml) was added. Then, a solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydrofuran (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

10 After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.47 ml) was added dropwise, and the mixture stirred at 0°C under nitrogen atmosphere for 20 minutes. Saturated aqueous solution (20 ml) of sodium bicarbonate was added thereto, and the resultant mixture stirred at room temperature for 30 minutes. Insoluble materials
15 were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (33% ethyl acetate/n-hexane) to obtain the title compounds, cis-isomer (248 mg) and trans-isomer (325 mg), respectively as white solid.

20 Each of the obtained isomers was dissolved in THF (7 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (7% methanol/chloroform) to obtain the objective compounds, cis-
25 isomer (99mg) and trans-isomer (149mg), as white solid.

trans-isomer

¹H NMR (DMSO-d₆) δ : 11.69(br.s, 1H), 7.86(s, 1H), 6.06(dd, 1H),
5.28(br.s, 1H), 2.37-2.24(m, 1H), 3.97-3.88(m, 1H), 3.67-3.63(m,
30 2H), 2.64-2.45(m, 1H), 2.29-2.20(m, 1H)

UV (H₂O) λ_{max} : 285.2 nm(pH 7), 286.4 nm(pH 2), 276.8 nm(pH 11)

cis-isomer

¹H NMR (DMSO-d₆) δ : 11.69(br.s, 1H), 8.15(s, 1H), 6.08(t, 1H),
4.25-4.17(m, 1H), 3.97-3.86(m, 1H), 3.72-3.67(m, 2H), 2.49-
2.42(m, 2H)

UV (H₂O) λ_{max} : 286.8 nm(pH 7), 286.2 nm(pH 2), 278.2 nm(pH 11)

Example 11 : 2-(Guanin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(17)

N²-Acetyl-O⁶-diphenylcarbamoyleguanine (355 mg) was suspended in dry 1,2-dichloroethane (15 ml), and N,O-bis(trimethylsilyl)acetamide (0.61 ml) was added thereto. The mixture was then heated under reflux with stirring under nitrogen atmosphere for 1 hour.

After cooling the reaction mixture to room temperature, a solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydrofuran (290 mg) in dry 1,2-dichloroethane (5 ml) was added thereto. After chilling the reaction mixture to 0 °C, trimethylsilyltrifluoromethane sulfonate (0.2 ml) was added dropwise, and the mixture stirred under nitrogen atmosphere for 1 hour. Saturated aqueous solution (10 ml) of sodium bicarbonate was added and the mixture stirred for 10 minutes. Separated organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. To the residue, saturated methanolic ammonia solution (10 ml) was added, and the mixture stirred at room temperature for 20 hours.

To the residue obtained after concentrating the mixture, THF (5 ml) was added, and then 1.0 M solution (0.5 ml) of tetrabutylammonium fluoride was added. The mixture was stirred at room temperature for 2 hours. After concentrating under reduced pressure, the residue was purified on a silica column (10% methanol/dichloromethane) to obtain the title compound (65 mg) as pale yellow solid.

¹H NMR (DMSO-d₆) δ : 10.80(bs, 1H), 7.98, 7.88(s each, 1H),
6.61(br, 2H), 6.05-6.25(m, 1H), 5.33(bs, 1H), 3.60-4.31(m, 4H),
2.50-2.81(m, 2H)
UV (H₂O) λ_{max} : 252, 271(sh) nm(pH 7), 254, 270(sh) nm(pH 2),
266 nm (pH 11)

Example 12 : 4-(t-Butyldiphenylsilyloxymethyl)-4-fluoro-2-(6-chloropurin-9-yl)tetrahydrofuran(18)

6-Chloropurine (150 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (15 ml), and ammonium sulfate (catalytic amount) and chlorotrimethylsilane (catalytic amount) were added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 4 hours. 1,1,1,3,3,3-hexamethyldisilazane was removed by evaporating under reduced pressure, and then dry 1,2-dichloroethane (10 ml) was added to the residue. Then, a solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydrofuran (200 mg) in dry 1,2-dichloroethane (5 ml) was added thereto.

After cooling the reaction mixture at 0°C, trimethylsilyl trifluoromethanesulfonate (0.19 ml) was added dropwise, and the resultant mixture was stirred at 0°C under nitrogen atmosphere for 20 minutes. Saturated aqueous solution (10 ml) of sodium bicarbonate was added to the reaction mixture, and the mixture stirred at room temperature for 10 minutes. Insoluble materials were filtered off, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (20% ethyl acetate/ n-hexane) to obtain the title compound (120 mg) as colorless caramel-like material.

Example 13 : 2-(6-Chloropurine-9-yl)-4-fluoro-4-hydroxymethyl tetrahydrofuran(19)

To a solution of 4-(t-butyldiphenylsilyloxymethyl)-4-fluoro-2-(6-

chloropurin-9-yl)tetrahydrofuran (100 mg) in tetrahydrofuran (5 ml), 1.0 M solution (0.2 ml) of tetrabutylammonium fluoride was added, and the mixture stirred at room temperature for 2 hours. After concentrating under reduced pressure, the residue was purified on a silica column (6% methanol/dichloromethane) to obtain the title compound (30 mg) as colorless caramel-like material.

¹H NMR (DMSO-d₆) δ : 9.00(s, 1H), 8.94(s, 1H), 6.75(t, 1H), 5.25(t, 1H), 4.20-4.54(m, 2H), 3.82-4.00(m, 2H), 2.88-3.21(m, 2H)

UV (H₂O) λ_{max} : 264.5nm (pH 7.2 및 11)

Example 14 : cis-2-(3-Carbamoyl-1,2,4-triazol-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(20) and trans-2-(3-carbamoyl-1,2,4-triazol-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran(21)

1,2,4-Triazol-3-carboxylatemethylester (304 mg) was suspended in dry 1,2-dichloroethane (15 ml), and N,O-bis(trimethylsilyl)acetamide (0.61 ml) was added thereto. The mixture was then heated under reflux with stirring under nitrogen atmosphere for 4 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (15 ml) was added. Then, a solution of 4-(t-butyl-diphenylsilyloxymethyl)-2-acetoxy-4-fluorotetrahydrofuran (500 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.47 ml) was added dropwise. The mixture stirred at 0°C under nitrogen atmosphere for 30 minutes and then stirred overnight at room temperature. Saturated aqueous solution (20 ml) of sodium bicarbonate was added thereto, and the resultant mixture stirred at room temperature for 30 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (60% ethyl acetate/n-

hexane) to obtain the pale yellow oil (350 mg).

The obtained oil was dissolved in THF (15 ml), and 1.0 M solution of tetrabutylammonium fluoride(0.89 ml) was added to the solution. The resultant mixture was stirred at room temperature for 2 hour and concentrated under reduced pressure. The residue was purified on a silica column (33% ethyl acetate/n-hexane) to obtain cis-isomer (60 mg) and trans-isomer (24.9 mg) respectively as the colorless oil.

To the obtained colorless oil, saturated methanolic ammonia solution (7 ml) was added. The mixture stirred under nitrogen atmosphere overnight and concentrated under reduced pressure.

The residue was purified on a silica column (5% methanol/ethyl acetate) to obtain the objective compounds, cis-isomer (33 mg) and trans-isomer (11 mg) as white solid.

trans-isomer

^1H NMR (DMSO- d_6) δ : 8.69(s, 1H), 7.79(br.s, 1H), 7.58(br.s, 1H), 6.26(dd, 1H), 5.36(br.s, 2H), 4.28-4.05(m, 2H), 3.67-3.61(m, 1H), 2.74-2.48(m, 2H)

cis-isomer

^1H NMR (DMSO- d_6) δ : 8.80(s, 1H), 7.83(br.s, 1H), 7.62(br.s, 1H), 6.46(t, 1H), 5.33(t, 1H), 4.16-4.03(m, 2H), 3.81-3.71(m, 2H), 2.78-2.68(m, 2H)

Example 15 : 4-(t-Butyldiphenylsilyloxymethyl)-4-methoxytetrahydrofuran-2-one(22)

To a solution of 4-(t-butyldiphenylsilyloxymethyl)-4-hydroxytetrahydrofuran-2-one (3 g) in iodomethane (10 ml), silver oxide (11.3 g) was added, and the mixture stirred at room temperature for 3 days. After filtered and concentrated under reduced pressure, the residue was purified on a silica column (25% ethyl acetate/n-hexane) to obtain the objective

compound(1.9 g) as yellow solution.

¹H NMR (DMSO-d₆) δ : 7.61-7.64(m, 4H), 7.39-7.47(m, 6H),
4.36(d, 1H), 4.29(d, 1H), 3.71(s, 2H), 3.23(s, 3H), 2.77(d, 1H),
2.60(d, 1H), 1.08(s, 9H)

Example 16 : 4-(t-Butyldiphenylsilyloxymethyl)-4-methoxytetrahydrofuran-2-ol(23)

After cooling a solution of 4-(t-butyldiphenylsilyloxymethyl)-4-methoxytetrahydrofuran-2-one, obtained in example 15, in dry dichloromethane (10 ml) to -78°C, the solution of 1.0 M diisobutylaluminium hydride (6 ml) was added dropwise. The mixture stirred at -78°C under nitrogen atmosphere for 10 minutes and then stirred overnight at room temperature. Saturated aqueous solution (10 ml) of potassium sodium tartrate was added thereto, and the resultant mixture stirred at room temperature for 20 hours. The organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The obtained yellowish solution was used in the following step without further purification.

Example 17 : 2-Acetoxy 4-(t-butyldiphenylsilyloxymethyl)-4-methoxytetra hydrofuran(24)

To the solution of 4-(t-butyldiphenylsilyloxymethyl)-4-methoxytetrahydrofuran-2-ol, obtained in example 16, in dry dichloromethane (5 ml), triethylamine (0.85 ml), acetic anhydride (0.6 ml) and 4-diethylaminopyridine (40 ml) were added dropwise. The resultant mixture was stirred at room temperature for 12 hours and concentrated under reduced pressure. The residue was purified on a silica column (100% ethyl acetate/n-hexane) to obtain the objective compound (1.2 g) as the yellowish solution.

¹H NMR (CDCl₃) δ : 7.64-7.68(m, 4H), 7.38-7.47(m, 6H),
6.40(dd, 0.64H), 6.23(dd, 0.36H), 4.08(d, 0.36H), 4.03(d, 0.26H),
4.02(s, 1.28H), 3.80(d, 0.69H), 3.74(d, 0.64H), 3.70(s, 0.72H),
3.01(s, 1.08H), 3.25(s, 1.92H), 2.38(dd, 0.72H), 2.15-2.30(m,
5 1.28H), 2.08(s, 1.08H), 1.99(s, 1.92H), 1.09(s, 5.76H), 1.08(s,
3.24H)

Example 18 : cis-2-(Thymin-1-yl)-4-methoxy-4-hydroxymethyltetrahydrofuran (25) and trans-2-(thymin-1-yl)-4-methoxy-4-hydroxymethyltetrahydrofuran(26)

Thymine (155 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (15 ml), and ammonium sulfate (catalytic amount) was added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 5 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (20 ml) was added. Then, a solution of 2-acetoxy-4-(t-butyl-diphenylsilyloxymethyl)-4-methoxytetrahydrofuran (263 mg) in dry 1,2-dichloroethane (5 ml) was added thereto.

After cooling the reaction mixture to 0°C, trimethylsilyl trifluoromethanesulfonate (0.24 ml) was added dropwise, and the mixture stirred at 0°C under nitrogen atmosphere for 10 minutes. Saturated aqueous solution (10 ml) of sodium bicarbonate was added thereto, and the resultant mixture stirred at room temperature for 30 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified on a silica column (ethyl acetate), recrystallized with dichloroethane/n-hexane (1:1) to obtain cis-isomer (35 mg) and trans-isomer (69 mg), respectively as pale yellow solid.

Each of the obtained isomers was dissolved in THF (1 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The

resultant mixture was stirred at room temperature for 2 hours and concentrated under reduced pressure. The residue was purified on a silica column (ethyl acetate) to obtain the objective compounds, cis-isomer (11.2mg) and trans-isomer (19.6mg), as pale yellow solid.

trans-isomer

^1H NMR (DMSO- d_6) δ : 11.23(br.s, 1H), 7.52(d, 1H), 6.01(dd, 1H), 4.93(t, 1H), 4.09(dd, 1H), 3.72(d, 1H), 3.57-3.49(m, 2H), 3.15(s, 3H), 2.33-2.28(m, 1H), 2.09-2.05(m, 1H), 1.77(s, 3H)

cis-isomer

^1H NMR (DMSO- d_6) δ : 11.25(br.s, 1H), 7.52(d, 1H), 6.06(t, 1H), 4.92(t, 1H), 4.02(d, 1H), 3.83(d, 1H), 3.64-3.53(m, 2H), 3.22(s, 3H), 2.34-2.29(m, 1H), 1.99-1.95(m, 1H), 1.77(s, 3H)

UV(H₂O) λ_{max} : 268 nm(pH 7), 267 nm(pH 2), 266.7 nm(pH 11)

Example 19 : (cis, trans)-2-(Cytosin-1-yl)-4-methoxy-4-hydroxymethyl tetrahydrofuran(27)

N⁴-Acetylcytosine (306 mg) was suspended in 1,1,1,3,3,3-hexamethyldisilazane (20 ml), and ammonium sulfate (catalytic amount) was added thereto. The mixture was heated under reflux with stirring under nitrogen atmosphere for 4 hours. Then, the mixture was evaporated under reduced pressure to remove 1,1,1,3,3,3-hexamethyldisilazane. To the residue, dry 1,2-dichloroethane (15 ml) was added to dissolve the residue. Then, a solution of 4-(t-butyldiphenylsilyloxymethyl)-2-acetoxy-4-fluorotetra hydrofuran (261 mg) in dry 1,2-dichloroethane (10 ml) was added thereto.

After cooling the reaction mixture to -10°C, trimethylsilyl trifluoromethanesulfonate (0.23 ml) was added dropwise, and the mixture stirred at -10°C under nitrogen atmosphere for 20 minutes. Saturated aqueous solution (25 ml) of sodium bicarbonate was added thereto, and the

resultant mixture stirred at room temperature for 10 minutes. Insoluble materials were removed by filtration, and the organic layer separated from the filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. To the obtained the pale yellow solution, saturated methanolic ammonia solution (7 ml) was added. The mixture stirred under nitrogen atmosphere for 30 minutes and concentrated under reduced pressure.

Each of the obtained isomers was dissolved in THF (15 ml), and 1.0 M solution of tetrabutylammonium fluoride was added to the solution. The resultant mixture was stirred at room temperature for 1 hour and concentrated under reduced pressure. The residue was purified on a silica column (10% methanol/chloroform) and recrystallized to obtain the objective compounds (64 mg) as white solid.

¹H NMR (DMSO-d₆) δ : 7.58(dd, 1H), 7.07(br.s, 1H), 6.98(br.s, 1H), 6.03(t, 0.38H), 5.95(dd, 0.62H), 5.70(m, 1H), 4.90(t, 0.38H), 4.07(d, 0.62H), 4.00(d, 0.38H), 3.83(d, 0.38H), 3.77(d, 0.62H), 3.56-3.61(m, 0.76H), 3.42-3.33(m, 1.24H), 3.20(s, 1.20H), 3.06(s, 1.80H), 2.37-2.30(m, 0.38H), 2.27-2.22(m, 0.62H), 1.96-1.88(m, 1H)

Example 20 : cis-2-(Cytosin-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuranhydrochloride(28)

cis-2-(Cytosin-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran (6mg) was added to methanolic hydrochloride solution and the resultant mixture was stirred for 20 min. After filtration, the mixture was dried by removing solvent under reduced pressure, and then methanol was added the residue for drying under reduced pressure. The residue was recrystallized in methanol to obtain the objective compound (5mg) as a white solid.

¹H NMR(DMSO-d₆) δ : 9.74(br. S, 1H), 8.65(br. S, 1H),

8.01-8.03(d, 1H), 6.13-6.11(m, 1H), 6.07(t, 1H), 4.27-4.15(m, 1H), 4.08-4.00(m, 1H), 3.73-3.62(m, 2H), 2.60-2.30(m, 2H)

UV(H₂O) λ_{\max} : 279, 220(sh) nm

5 **Test of anti-HBV activity**

The anti-HBV activity of the compounds according to the present invention, was tested in Hep G2 2.2.15 cell lines, as using 2',3'-dideoxycytidine as a control compound. The results are shown in Table 1.


10 Table 1: Anti-HBV activity of the compounds

Test Compound	EC ₅₀ (μ M)	EC ₉₀ (μ M)	CC ₅₀ (μ M)	SI (CC ₅₀ /EC ₉₀)
5 (Example 5)	0.1	0.8	472	590
6 (Example 5)	0.2	1.0	2,321	2,321
7 (Example 6)	0.011	0.143	1,546	10,811
8 (Example 6)	0.080	0.522	1,500	2,874
9 (Example 7)	0.8	0.7	2,232	319
10 (Example 7)	0.061	0.835	955	1,444
15 (Example 10)	0.6	4.4	2,203	501
16 (Example 10)	0.8	5.3	451	85
Control compound	7.57	35.035	1,079.443	30.811

As shown in the Table 1 above, compounds of the present invention have excellent anti-HBV effect with low toxicity.

CLAIMS

1. A nucleoside derivative represented by the following general formula(I):




wherein R₁ represents hydrogen, phosphate, phosphonate, alkyl or acyl, R₂ represents alkoxy or halogen, R₃ represents substituted or non-substituted pyrimidine or purine base, and X represents O, S, SO or SO₂; stereoisomers thereof or a mixture of these isomers, and pharmaceutically acceptable salts thereof.

2. A nucleoside derivative according to claim 1, wherein the compound is cis isomer.


3. A nucleoside derivative according to claim 1, wherein the compound is trans isomer.

4. A nucleoside derivative according to one of claims 1 to 3, in which R₃ of the general formula (I) is selected from the following groups:



wherein R_4 represents hydrogen, saturated or unsaturated alkyl which may have (a) substituent(s), or halogen, R_5 represents hydrogen, hydroxy, alkoxy, saturated or unsaturated alkyl which may have (a) substituent(s), or saturated or unsaturated acyl which may have (a) substituent(s), R_6 represents hydrogen, cyano, carboxyl, alkoxycarbonyl, carbamoyl or thiocarbamoyl, and R_7 and R_8 each represents hydrogen, hydroxy, amino or halogen.

5. A nucleoside derivative according to one of claims 1 to 3, in which R_1 represents hydrogen, phosphate or phosphonate, R_2 represents alkoxy or halogen, and R_3 represents groups represented by the following formulas, and X represents O or S;



wherein R_9 represents hydrogen, methyl, hydroxymethyl, methoxymethyl, methylthiomethyl, trifluoromethyl, ethyl, propyl, cyclopropyl, vinyl, 2-bromovinyl, fluoro, chloro, bromo or iodo, R_{10} represents hydrogen, methyl, ethyl, hydroxy, methoxy or C_1 - C_{16} acyl, R_{11} represents hydrogen, cyano, carboxyl, alkoxycarbonyl, carbamoyl or thiocarbamoyl, and R_{12} and R_{13} each represents hydrogen, hydroxy, amino, fluoro, chloro, bromo or iodo;

6. A nucleoside derivative according to claim 1, which is selected from a group consisting of cis-2-(uracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(uracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(thymine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(thymine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(5-fluorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(5-fluorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(5-chlorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(5-chlorouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(5-bromouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(5-bromouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(5-iodouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(5-iodouracil-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-[5-(trans-2-bromovinyl)uracil-1-yl]-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-[5-(trans-2-bromovinyl)uracil-1-yl]-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(cytosine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(cytosine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(5-fluorocytosine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(5-fluorocytosine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(5-methylcytosine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(5-methylcytosine-1-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(adenine-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(adenine-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(6-hydroxypurin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(6-hydroxypurin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(6-methylaminopurin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, trans-2-(6-methylaminopurin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(6-chloropurin-9-yl)-4-fluoro-4-hydroxymethyl

5 tetrahydrofuran, trans-2-(6-chloropurin-9-yl)-4-fluoro-4-hydroxymethyl tetrahydrofuran, and mixtures thereof; cis-2-(2-fluoroadenin-9-yl)-4-fluoro-4-hydroxymethyltetrahydro furan, trans-2-(2-fluoroadenin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(2-amino-6-chloropurin-9-yl)-4-fluoro-4-hydroxymethyltetra hydrofuran, trans-2-(2-amino-6-chloropurin-9-yl)-4-fluoro-4-hydroxymethyltetra hydrofuran, and mixtures thereof; cis-2-(guanin-9-yl)-4-fluoro-4-hydroxymethyltetrahydro furan, trans-2-(guanin-9-yl)-4-fluoro-4-hydroxymethyltetrahydrofuran, and mixtures thereof; cis-2-(3-carbamoyl-1,2,4-triazol-1-yl)-4-fluoro-4-hydroxy methyltetrahydrofuran, trans-2-(3-carbamoyl-1,2,4-triazol-1-yl)-4-fluoro-4-hydroxy methyltetrahydrofuran, and mixtures thereof; cis-2-(thymin-1-yl)-4-methoxy-4-hydroxymethyltetrahydrofuran, trans-2-(thymin-1-yl)-4-methoxy-4-hydroxymethyl tetrahydrofuran, and mixtures thereof; cis-2-(3-carbamoyl-1,2,4-triazol-1-yl)-4- methoxy-4-hydroxymethyltetrahydrofuran, trans-2-(3-carbamoyl-1,2,4-triazol-1-yl)-4-methoxy-4-hydroxymethyltetra hydrofuran, and mixtures thereof; cis-2-(cytosin-1-yl)-4-methoxy-4-hydroxymethyltetrahydrofuran, trans-2-(cytosin-1-yl)-4-methoxy-4-hydroxy methyltetrahydrofuran, and mixtures thereof; and pharmaceutically acceptable salts of these compounds.

20

7. A nucleoside derivative according to claim 1, which is in the form of hydrochloric acid salt.

25

8. A nucleoside derivative according to claim 1, which is in the form of racemic mixture.


9. A nucleoside derivative according to claim 1, which is in the form of optically pure enantiomer.

30

10. An antiviral agent comprising the compound (I) according to claim 1 or a pharmaceutically acceptable salt thereof.

11. An anti-HBV agent comprising the compound (I) according to claim 1 or a pharmaceutically acceptable salt thereof.


5 12. A compound represented by the following formula (IV) :



wherein R_{14} represents hydrogen or protective group for hydroxyl group, R_{15} represents alkoxy or halogen, L represents acyl, halide or alkoxy group, and X represents O, S, SO or SO_2 ;

10 structural or stereoisomers thereof, and the mixture of these isomers.

13. A process for preparing a compound represented by general formula (I) which comprises the step of reacting a compound represented by general formula (IV) with a base (R_3H) in the presence of a Lewis acid;



15 wherein R_1 represents hydrogen, phosphate, phosphonate, alkyl or acyl, R_2 represents alkoxy or halogen, R_3 represents substituted or non-substituted pyrimidine or purine base, and X represents O, S, SO or SO_2 , R_{14} represents hydrogen or protective group for hydroxyl group, R_{15} represents alkoxy or halogen, L represents acyl, alkoxy group or halide.

20

14. A process according to claim 13, wherein the compound (I) is obtained as an optically pure enantiomer.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00189

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 07 H 19/04, 19/056, 19/06, 19/10, 19/12, 19/16, 19/20, 5/02, 5/10, 13/02, 15/04

According to International Patent Classification (IPC) or to both national classification and IPC // A 61 K 31/70

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 07 H; A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DARC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	Chemical Abstracts, Vol.123, No.19, 06 November 1995 (Columbus, Ohio, USA), page 1209, column 2, abstract No.257236f, HAMMERSCHMIDT, F. et al.: "Convenient route to D-apio- β -D-furanosyl- and 2'-deoxyapio- β -D-furanosyl nucleosides", & Liebig's Ann. 1995, (3), 551-8 (Ger).	1-14
A	EP 0 515 156 A1 (BIOCHEM PHARMA INC.) 25 November 1992 (25.11.92), claims.	1-14
A	WO 92/06 102 A1 (MEDIVIR AB) 16 April 1992 (16.04.92), claims.	1-14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 January 1997 (10.01.97)

Date of mailing of the international search report

21 January 1997 (21.01.97)

Name and mailing address of the ISA/ AT
AUSTRIAN PATENT OFFICE
Kohlmarkt 8-10
A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Schnass

Telephone No. 1/5337058/35

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 96/00189

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication		Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets		Datum der Veröffentlichung Publication date Date de publication	
EP A1	515156	25-11-92		AT E	133958	15-02-93	
				AU A1	163947	06-11-93	
				AU A1	163948	06-11-93	
				AU A1	163949	06-11-93	
				AU A1	163950	06-11-93	
				AU A1	163951	06-11-93	
				AU A1	163952	06-11-93	
				AU A1	163953	06-11-93	
				AU A1	163954	06-11-93	
				AU A1	163955	06-11-93	
				AU A1	163956	06-11-93	
				AU A1	163957	06-11-93	
				AU A1	163958	06-11-93	
				AU A1	163959	06-11-93	
				AU A1	163960	06-11-93	
				AU A1	163961	06-11-93	
				AU A1	163962	06-11-93	
				AU A1	163963	06-11-93	
				AU A1	163964	06-11-93	
				AU A1	163965	06-11-93	
				AU A1	163966	06-11-93	
				AU A1	163967	06-11-93	
				AU A1	163968	06-11-93	
				AU A1	163969	06-11-93	
				AU A1	163970	06-11-93	
				AU A1	163971	06-11-93	
				AU A1	163972	06-11-93	
				AU A1	163973	06-11-93	
				AU A1	163974	06-11-93	
				AU A1	163975	06-11-93	
				AU A1	163976	06-11-93	
				AU A1	163977	06-11-93	
				AU A1	163978	06-11-93	
				AU A1	163979	06-11-93	
				AU A1	163980	06-11-93	
				AU A1	163981	06-11-93	
				AU A1	163982	06-11-93	
				AU A1	163983	06-11-93	
				AU A1	163984	06-11-93	
				AU A1	163985	06-11-93	
				AU A1	163986	06-11-93	
				AU A1	163987	06-11-93	
				AU A1	163988	06-11-93	
				AU A1	163989	06-11-93	
				AU A1	163990	06-11-93	
				AU A1	163991	06-11-93	
				AU A1	163992	06-11-93	
				AU A1	163993	06-11-93	
				AU A1	163994	06-11-93	
				AU A1	163995	06-11-93	
				AU A1	163996	06-11-93	
				AU A1	163997	06-11-93	
				AU A1	163998	06-11-93	
				AU A1	163999	06-11-93	
				AU A1	164000	06-11-93	
				AU A1	164001	06-11-93	
				AU A1	164002	06-11-93	
				AU A1	164003	06-11-93	
				AU A1	164004	06-11-93	
				AU A1	164005	06-11-93	
				AU A1	164006	06-11-93	
				AU A1	164007	06-11-93	
				AU A1	164008	06-11-93	
				AU A1	164009	06-11-93	
				AU A1	164010	06-11-93	
				AU A1	164011	06-11-93	
				AU A1	164012	06-11-93	
				AU A1	164013	06-11-93	
				AU A1	164014	06-11-93	
				AU A1	164015	06-11-93	
				AU A1	164016	06-11-93	
				AU A1	164017	06-11-93	
				AU A1	164018	06-11-93	
				AU A1	164019	06-11-93	
				AU A1	164020	06-11-93	
				AU A1	164021	06-11-93	
				AU A1	164022	06-11-93	
				AU A1	164023	06-11-93	
				AU A1	164024	06-11-93	
				AU A1	164025	06-11-93	
				AU A1	164026	06-11-93	
				AU A1	164027	06-11-93	
				AU A1	164028	06-11-93	
				AU A1	164029	06-11-93	
				AU A1	164030	06-11-93	
				AU A1	164031	06-11-93	
				AU A1	164032	06-11-93	
				AU A1	164033	06-11-93	
				AU A1	164034	06-11-93	
				AU A1	164035	06-11-93	
				AU A1	164036	06-11-93	
				AU A1	164037	06-11-93	
				AU A1	164038	06-11-93	
				AU A1	164039	06-11-93	
				AU A1	164040	06-11-93	
				AU A1	164041	06-11-93	
				AU A1	164042	06-11-93	
				AU A1	164043	06-11-93	
				AU A1	164044	06-11-93	
				AU A1	164045	06-11-93	
				AU A1	164046	06-11-93	
				AU A1	164047	06-11-93	
				AU A1	164048	06-11-93	
				AU A1	164049	06-11-93	
				AU A1	164050	06-11-93	
				AU A1	164051	06-11-93	
				AU A1	164052	06-11-93	
				AU A1	164053	06-11-93	
				AU A1	164054	06-11-93	
				AU A1	164055	06-11-93	
				AU A1	164056	06-11-93	
				AU A1	164057	06-11-93	
				AU A1	164058	06-11-93	
				AU A1	164059	06-11-93	
				AU A1	164060	06-11-93	
				AU A1	164061	06-11-93	
				AU A1	164062	06-11-93	
				AU A1	164063	06-11-93	
				AU A1	164064	06-11-93	
				AU A1	164065	06-11-93	
				AU A1	164066	06-11-93	
				AU A1	164067	06-11-93	
				AU A1	164068	06-11-93	
				AU A1	164069	06-11-93	
				AU A1	164070	06-11-93	
				AU A1	164071	06-11-93	
				AU A1	164072	06-11-93	
				AU A1	164073	06-11-93	
				AU A1	164074	06-11-93	
				AU A1	164075	06-11-93	
				AU A1	164076	06-11-93	
				AU A1	164077	06-11-93	
				AU A1	164078	06-11-93	
				AU A1	164079	06-11-93	
				AU A1	164080	06-11-93	
				AU A1	164081	06-11-93	
				AU A1	164082	06-11-93	
				AU A1	164083	06-11-93	
				AU A1	164084	06-11-93	
				AU A1	164085	06-11-93	
				AU A1	164086	06-11-93	
				AU A1	164087	06-11-93	
				AU A1	164088	06-11-93	
				AU A1	164089	06-11-93	
				AU A1	164090	06-11-93	
				AU A1	164091	06-11-93	
				AU A1	164092	06-11-93	
				AU A1	164093	06-11-93	
				AU A1	164094	06-11-93	
				AU A1	164095	06-11-93	
				AU A1	164096	06-11-93	
				AU A1	164097	06-11-93	
				AU A1	164098	06-11-93	
				AU A1	164099	06-11-93	
				AU A1	164100	06-11-93	
				AU A1	164101	06-11-93	
				AU A1	164102	06-11-93	
				AU A1	164103	06-11-93	
				AU A1	164104	06-11-93	
				AU A1	164105	06-11-93	
				AU A1	164106	06-11-93	
				AU A1	164107	06-11-93	
				AU A1	164108	06-11-93	
				AU A1	164109	06-11-93	
				AU A1	164110	06-11-93	
				AU A1	164111	06-11-93	
				AU A1	164112	06-11-93	
				AU A1	164113	06-11-93	
				AU A1	164114	06-11-93	
				AU A1	164115	06-11-93	
				AU A1	164116	06-11-93	
				AU A1	164117	06-11-93	
				AU A1	164118	06-11-93	
				AU A1	164119	06-11-93	
				AU A1	164120	06-11-93	
				AU A1	164121	06-11-93	
				AU A1	164122	06-11-93	
				AU A1	164123	06-11-93	
				AU A1	164124	06-11-93	
				AU A1	164125	06-11-93	
				AU A1	164126	06-11-93	
				AU A1	164127	06-11-93	
				AU A1	164128	06-11-93	
				AU A1	164129	06-11-93	
				AU A1	164130	06-11-93	
				AU A1	164131	06-11-93	
				AU A1	164132	06-11-93	
				AU A1	164133	06-11-93	
				AU A1	164134	06-11-93	
				AU A1	164135	06-11-93	
				AU A1	164136	06-11-93	
				AU A1	164137	06-11-93	
				AU A1	164138	06-11-93	
				AU A1	164139	06-11-93	
				AU A1	164140	06-11-93	
				AU A1	164141	06-11-93	
				AU A1	164142	06-11-93	
				AU A1	164143	06-11-93	
				AU A1	164144	06-11-93	
				AU A1	164145	06-11-93	
				AU A1	164146	06-11-93	
				AU A1	164147	06-11-93	
				AU A1	164148	06-11-93	
				AU A1	164149	06-11-93	
				AU A1	164150	06-11-93	
				AU A1	164151	06-11-93	